^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epirubicin

    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    3d
    TARMAC: MicroRNA Profiles in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, University College Hospital, Ibadan | Trial completion date: Aug 2023 --> Aug 2030 | Trial primary completion date: Mar 2023 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
    10d
    GIM2: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=2000, Active, not recruiting, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    paclitaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim)
    19d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    27d
    MRG003-SACC: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Eye & ENT Hospital of Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    epirubicin • Meiyouheng (becotatug vedotin)
    1m
    VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=26, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=60 --> 26 | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • epirubicin • prednisone
    1m
    Effective Management of Chemotherapy-Induced Cardiotoxicity: A Prospective Follow-Up Study on Alternative Regimens in Bangladeshi Cancer Patients. (PubMed, Cureus)
    Initial regimens included doxorubicin (42%), epirubicin (18%), taxanes (paclitaxel/docetaxel/nab-paclitaxel; 25%), and fluoropyrimidines (5-fluorouracil/capecitabine; 15%), all discontinued due to toxicity. Patients were switched to liposomal doxorubicin (n=73) or non-anthracycline protocols (e.g., gemcitabine-based; n=39)...In resource-limited settings like Bangladesh, prioritizing liposomal formulations for high-risk patients could mitigate cardiotoxicity burdens. Integrated cardio-oncology protocols are recommended.
    Journal
    |
    NPPB (Natriuretic Peptide B)
    |
    gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • epirubicin
    1m
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    1m
    NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov)
    P2, N=29, Completed, Guangdong Provincial People's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2ms
    BRCA2 Reversion Mutation after Neoadjuvant Dose-Dense EC and Dose-Dense Paclitaxel in Triple-Negative Breast Cancer: A Case Report and Literature Review. (PubMed, Surg Case Rep)
    This case suggests that a BRCA2 reversion mutation can arise early, even before PARPi or platinum exposure. Serial monitoring of BRCA status may help predict therapeutic resistance in patients with germline BRCA-mutated breast cancer.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA mutation
    |
    paclitaxel • cyclophosphamide • epirubicin
    2ms
    Biomimic colloidal self-assembly of epirubicin/ferric ion multi-enzyme delivery for synergistic photothermal therapy of metastatic triple-negative breast cancer. (PubMed, Colloids Surf B Biointerfaces)
    PEF NDs had no detrimental effects on vital organs (heart, kidney, liver, lung, or spleen), indicating acceptable in vivo biosafety. Self-assembled nanodrugs with simultaneous photothermal and anti-inflammatory properties have considerable clinical potential in the treatment of metastatic malignancies.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9) • CAT (Catalase)
    |
    epirubicin
    2ms
    OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)
    P3, N=3380, Not yet recruiting, UNICANCER
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    2ms
    A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=43, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin